Basel, 27 January 2020
Invitation to Roche’s Virtual Early Drug Development gRED Event 2020
We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Tuesday, February 18, 2020 , highlighting Roche’s early drug development with a focus on Genentech Research and Early Development (gRED).
We would like to invite all interested parties to dial in as outlined below:
Tuesday, February 18, 2020
15:30 – 17:00 CET/ 14:30 – 16:00 GMT
9:30 am – 11:00 am EST / 6:30 am – 8:00 am PST
Video webcast and conference call will start with presentations by senior researchers followed by a Q&A session (live access to the speakers).
Karl Mahler, Head of Investor Relations and Roche Group Planning
- Overview and Introduction to Genentech (gRED)
Michael Varney, Head of Genentech Research and Early Development
- Non-Oncology Pipeline Overview
Andy Chan, Senior Vice President, Research Biology for gRED
- Oncology Pipeline Overview
Stuart Lutzker, Vice President, Oncology Research and ad interim Head of Early Clinical Development for gRED
- Cancer Immunotherapy
Ira Mellman, Vice President, Cancer Immunology and Immunology for gRED
Access to Video webcast
Please access by clicking on ir.roche.com.
Access to Conference Call (pre-registration required)
You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.
Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start:
+41 (0) 58 310 50 00 (Europe & RoW)
+44 (0) 207 107 06 13 (UK)
+1 (1) 631 570 5613 (USA)
A replay of the webcast will be available via ir.roche.com.